Amarin Corp ADR(AMRN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.3 | Insider Own | 0.02% | Shs Outstand | 21.0M | Perf Week | 2.48% |
| Market Cap | 0.29B | Forward P/E | - | EPS next Y | 42.55% | Insider Trans | - | Shs Float | 21.0M | Perf Month | 0.21% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.1 | Inst Own | 136.57% | Short Float | 2.5% | Perf Quarter | -4.88% |
| Income | -0.03B | P/S | 1.59 | EPS this Y | -565.48% | Inst Trans | 0.1% | Short Ratio | 6.81 | Perf Half Y | -13.97% |
| Sales | 0.19B | P/B | 0.66 | EPS next 5Y | - | ROA | -4.18% | Short Interest | 0.53M | Perf YTD | 0.61% |
| Book/sh | 21.12 | P/C | 0.94 | EPS past 3/5Y | 29.16% -14.55% | ROE | -5.96% | 52W High | -32.82% ($20.90) | Perf Year | -6.37% |
| Cash/sh | 14.99 | P/FCF | 18.96 | Sales past 3/5Y | -16.59% -19.12% | ROIC | -6.03% | 52W Low | 8.33% ($12.96) | Perf 3Y | -30.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 74.2% | Gross Margin | 40.42% | Volatility(W/M) | 3.53% 3.36% | Perf 5Y | -86.75% |
| Dividend TTM | - | EV/Sales | -0.08 | Sales Y/Y TTM | -15.63% | Oper. Margin | -12.88% | ATR (14) | 0.51 | Perf 10Y | -77.85% |
| Dividend Ex-Date | - | Quick Ratio | 2.67 | EPS Q/Q | 46.7% | Profit Margin | -14.57% | RSI (14) | 48.91 | Recom | 5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.67 | Sales Q/Q | -42.58% | SMA20 | 0.02% ($14.04) | Beta | 0.75 | Target Price | $12.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/29 | SMA50 | -1.7% ($14.28) | Rel Volume | 0.67 | Prev Close | $14.39 |
| Employees | 80 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -100% -5.25% | SMA200 | -4.55% ($14.71) | Avg Volume(3M) | 0.08M | Price | $14.04 |
| IPO | 1993/4/1 | Option/Short | Yes/Yes | Trades | 588 | Volume | 51,757 | Change | -2.43% |
Company
AMRN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Amarin is a pharmaceutical company focused on reducing the risk of cardiovascular disease. Its flagship product is Vascepa (generic name: icosapent ethyl), a prescription drug based on a purified omega-3 fatty acid (EPA), and the company operates in the area of cardiovascular risk management for patients with high triglyceride levels. It is a small pharmaceutical company pursuing expansion in the U.S. and global markets.
Over the past 1 year, on the lower side
33% below its 1-year high.
AMRN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -565.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Sell.
Tap to view numbers
Holding long would have lost money
Would have changed by -30.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 136.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
GWX 0.00%
RACK 0.00%
SPDW 0.00%It ranks #4 in the industry
Based on market cap of $295M.
AMRN $295M PER -
LLY $1.1T PER 38.2
JNJ $642B PER 30.9
ABBV $451B PER 72.1
FAQ
What kind of company is AMRN?
AMRN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of AMRN?
The market cap of AMRN is approximately $295M, ranking 3,742 within its sector.
What is the 52-week high and low for AMRN?
AMRN has recorded a 52-week high of $20.90 and a low of $12.96.
